


## PHARMACEUTICAL 2017



## NightHawk Biosciences Inc. Rank 210 of 292





## PHARMACEUTICAL 2017



## NightHawk Biosciences Inc. Rank 210 of 292

The relative strengths and weaknesses of NightHawk Biosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NightHawk Biosciences Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 30% points. The greatest weakness of NightHawk Biosciences Inc. is the variable Net Income, reducing the Economic Capital Ratio by 125% points.

The company's Economic Capital Ratio, given in the ranking table, is -18%, being 21% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	8,263
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,595
Liabilities, Non-Current	461
Other Assets	274
Other Compr. Net Income	415
Other Expenses	0
Other Liabilities	0
Other Net Income	494
Other Revenues	0
Property and Equipment	360
Research and Development	9,331
Selling, General and Administrative Expense	4,138

Output Variable	Value in 1000 USD
Assets	8,897
Liabilities	2,057
Expenses	13,469
Revenues	0
Stockholders Equity	6,840
Net Income	-12,975
Comprehensive Net Income	-12,767
Economic Capital Ratio	-18%

